Press releasePRNewswire
Disc Medicine
IRON · NASDAQ
$79.48+$0.55 (+0.70%)TodayMarket closed ·
Prev close $78.93
Latest news
- NewsShivdeep Dhaliwal
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
- NewsAvi Kapoor
Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsVandana Singh
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
- NewsAvi Kapoor
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
- NewsRishabh Mishra
Stock Market Today: Dow Futures Drop, S&P 500, Nasdaq 100 Rise as Scott Bessent Links September Inflation to 'Energy Shock'— RCAT, ESLT, STLD in Focus (UPDATED)
- Press releaseGlobe Newswire
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
- News
10 Health Care Stocks With Whale Alerts In Today’s Session
- Press releaseNewsfile
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseGlobe Newswire
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
- Press releaseNewsfile
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, A LEADING NATIONAL FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseGlobe Newswire
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
- Press releasePRNewswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releasePRNewswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON
- Press releasePRNewswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- NewsVandana Singh
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones
- Press releaseGlobe Newswire
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
- Press releaseNewsfile
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releasePRNewswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseNewsfile
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
- Press releaseGlobe Newswire
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
- Press releaseGlobe Newswire
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
- Press releaseGlobe Newswire
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates
- NewsAvi Kapoor
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings
- NewsAvi Kapoor
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday
- NewsAvi Kapoor
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday
- News
12 Health Care Stocks Moving In Monday's Intraday Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.